Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 1 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,180 | -14.7% | 1,501 | +6.2% | 0.00% | – |
Q2 2023 | $9,594 | +31880.0% | 1,413 | -76.0% | 0.00% | -100.0% |
Q1 2023 | $30 | +900.0% | 5,899 | +924.1% | 0.00% | – |
Q4 2022 | $3 | -100.0% | 576 | -63.6% | 0.00% | – |
Q3 2022 | $23,000 | -63.5% | 1,584 | -62.1% | 0.00% | -100.0% |
Q2 2022 | $63,000 | +85.3% | 4,184 | +45.3% | 0.00% | – |
Q1 2022 | $34,000 | -34.6% | 2,880 | -9.3% | 0.00% | -100.0% |
Q4 2021 | $52,000 | -18.8% | 3,175 | +41.6% | 0.00% | -50.0% |
Q3 2021 | $64,000 | +4.9% | 2,243 | +25.0% | 0.00% | 0.0% |
Q2 2021 | $61,000 | -50.0% | 1,795 | -55.7% | 0.00% | 0.0% |
Q1 2021 | $122,000 | -11.6% | 4,049 | +44.7% | 0.00% | -50.0% |
Q4 2020 | $138,000 | +273.0% | 2,799 | +189.5% | 0.00% | – |
Q3 2020 | $37,000 | -68.1% | 967 | -64.0% | 0.00% | -100.0% |
Q2 2020 | $116,000 | +582.4% | 2,683 | +386.1% | 0.01% | +400.0% |
Q4 2019 | $17,000 | 0.0% | 552 | -25.4% | 0.00% | 0.0% |
Q2 2019 | $17,000 | +183.3% | 740 | +244.2% | 0.00% | – |
Q1 2019 | $6,000 | -14.3% | 215 | -39.8% | 0.00% | -100.0% |
Q4 2018 | $7,000 | – | 357 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $932,939 | 3.08% |
Sofinnova Investments, Inc. | 2,194,278 | $10,708,077 | 0.64% |
Artal Group S.A. | 400,000 | $1,952 | 0.11% |
Polar Capital Holdings Plc | 1,991,929 | $9,720,614 | 0.08% |
ASHFORD CAPITAL MANAGEMENT INC | 98,870 | $482,486 | 0.08% |
Soleus Capital Management, L.P. | 87,182 | $425,448 | 0.06% |
GSA CAPITAL PARTNERS LLP | 99,160 | $484 | 0.06% |
Cormorant Asset Management, LP | 150,000 | $732 | 0.05% |
CORNERCAP INVESTMENT COUNSEL INC | 48,233 | $235,377 | 0.04% |
XTX Topco Ltd | 38,574 | $188,241 | 0.04% |